CN111686132B - Syngnathus sterol solid dispersion and application thereof in treating cerebral apoplexy - Google Patents
Syngnathus sterol solid dispersion and application thereof in treating cerebral apoplexy Download PDFInfo
- Publication number
- CN111686132B CN111686132B CN202010543615.4A CN202010543615A CN111686132B CN 111686132 B CN111686132 B CN 111686132B CN 202010543615 A CN202010543615 A CN 202010543615A CN 111686132 B CN111686132 B CN 111686132B
- Authority
- CN
- China
- Prior art keywords
- syngnathus
- sterol
- solid dispersion
- cholest
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Steroid Compounds (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to a solid dispersion of Syngnathus sterol and application thereof in treating cerebral apoplexy. The solid dispersion of the syngnathus sterol comprises a syngnathus sterol extract and polyvinylpyrrolidone, wherein the syngnathus sterol extract is prepared by adding a soluble calcium salt solution for precipitation after the syngnathus is extracted by an alkaline methanol aqueous solution, and then carrying out acetone reflux and recrystallization; and the preparation method is simple, is suitable for large-scale industrial production and has wide application range.
Description
Technical Field
The invention belongs to the technical field of biological medicines. More particularly, relates to a solid dispersion of Syngnathus sterol and its application in treating cerebral apoplexy.
Background
Syngnathus is a marine traditional Chinese medicinal material in China, has a habit of taking Syngnathus in folk, is used for stewing soup, has the effects of relieving swelling and resolving masses, and can be used for treating diseases such as abdominal mass accumulation, scrofula and gall, traumatic injury, carbuncle, swelling, furuncle and the like. The existing research finds that the active substances contained in the sea dragon have better curative effect on diseases such as tumor, hyperplasia and the like, for example, Chinese patent application CN1793174A discloses an anti-tumor active protein of the sea dragon, and experiments prove that the active protein extracted from the sea dragon has anti-tumor activity alone or in combination with other medicines, and has the characteristics of low toxicity and immunity enhancement; chinese patent application CN101019892A discloses a syngnathus solid dispersion, its preparation method and application, the solid dispersion is prepared from syngnathus zymolyte obtained by enzymolysis, deodorization and other steps and polyvinylpyrrolidone, and has good curative effect on prostatic hyperplasia and hyperplasia of mammary glands diseases, and low toxicity. However, the application of the Syngnathus, the Syngnathus extract or the preparation in the aspect of cerebral apoplexy diseases has not been researched, and the effect is not clear.
Stroke (Stroke), also known as cerebrovascular accident or Stroke, is an acute cerebrovascular disease manifested by circulatory disturbance of cerebral blood flow and functional or structural damage of brain tissue due to cerebrovascular occlusion and rupture, and has become the second most common cause of death worldwide in recent years, before cancer. It is reported that the risk of stroke in people over 65 years old is as high as two thirds, ranked after heart disease and before cancer, with south asian people having a particularly high risk of stroke accounting for 40% of global stroke deaths. In addition, the stroke not only harms the health of people with high morbidity, high mortality and high disability rate, but only about 10 percent of the surviving stroke patients accounting for 80 percent of the patients can completely recover the normal functions, and most of the patients have sequelae of hemiplegia, aphasia and the like, thereby causing serious burden to the society and families.
At present, the method for clinically treating the cerebral apoplexy mainly comprises the steps of taking aspirin, clopidogrel, a brain active tablet, Mikebao and the like, and the drug effect of the method is mainly to eliminate local embolism of the cerebral apoplexy. However, most of the above drugs are chemical drugs, and after ingestion, the body has various side effects, which is poor in safety, and the peripheral immunosuppression is reduced due to ischemia-reperfusion injury while the embolism is relieved. Therefore, it is necessary to develop a novel medicament for treating stroke, which can improve peripheral immunosuppression while treating stroke, and achieve better therapeutic effect.
Disclosure of Invention
The invention aims to solve the technical problems that the existing clinical treatment medicine for cerebral apoplexy has poor safety and is easy to cause the problems of reduction of peripheral immune suppression and the like, and provides a novel solid dispersion of Syngnathus sterol for treating cerebral apoplexy, which can improve peripheral immune suppression while treating cerebral apoplexy, achieves better treatment effect and has higher safety.
The invention aims to provide a solid dispersion of Syngnathus sterol.
The invention also aims to provide the application of the solid dispersion of the syngnathus sterol in preparing the drugs for preventing and treating the cerebral apoplexy or peripheral immunosuppression caused by the cerebral apoplexy.
The above purpose of the invention is realized by the following technical scheme:
a Syngnathus sterol solid dispersion comprises Syngnathus sterol extract and polyvinylpyrrolidone, wherein the Syngnathus sterol extract is prepared by extracting Syngnathus with alkaline methanol water solution, adding soluble calcium salt solution for precipitation, refluxing with acetone, and recrystallizing;
the preparation method of the alkaline methanol aqueous solution comprises the following steps: methanol and water are mixed according to the volume ratio (0.125-10): 1, and adding 1-20 wt% of sodium hydroxide or potassium hydroxide to obtain the catalyst.
Further, the mass ratio of the Syngnathus sterol extract to the polyvinylpyrrolidone is 1 (1-40). In practice, the solid dispersion prepared from the Syngnathus sterol extract and polyvinylpyrrolidone can remarkably improve the solubility of Syngnathus sterol in an aqueous solution and remarkably improve the absorption and pharmacological effects of Syngnathus sterol.
Preferably, the mass ratio of the Syngnathus sterol extract to the polyvinylpyrrolidone is 1 (2-25).
Preferably, the mass ratio of the Syngnathus sterol extract to the polyvinylpyrrolidone is 1 (2-16).
More preferably, the mass ratio of the Syngnathus sterol extract to the polyvinylpyrrolidone is 1 (4-15).
Further, the preparation method of the solid dispersion of the Syngnathus sterol specifically comprises the following steps:
s1, crushing the dried sea dragon, adding an alkaline methanol aqueous solution, heating to reflux for 4-12 h, and filtering at normal temperature to obtain a filtrate;
s2, adding soluble calcium salt dropwise into the filtrate obtained in the step S2 while stirring until no precipitate is separated out, standing, and filtering to obtain precipitate Syngnathus sterol calcium salt;
s3, adding acetone into the precipitate, heating to reflux, filtering, concentrating the filtrate to 10-30% of the original volume, cooling and crystallizing, washing the crystals with ethanol at 4 ℃, filtering, collecting the crystals, and drying to obtain a Syngnathus sterol extract;
s4, dissolving the Syngnathus sterol extract obtained in the step S3 in ethanol, adding polyvinylpyrrolidone, dissolving, mixing uniformly, and spray drying to obtain the Syngnathus sterol solid dispersion.
Further, in step S1, the weight-to-volume ratio of the dried sea dragon product to the alkaline methanol aqueous solution is (0.05-0.5): 1 g/ml.
Furthermore, in step S3, the weight/volume ratio of the precipitate to acetone is 1 (10-20) g/ml.
Further, the Syngnathus sterol extract comprises the following sterol components: 24-dehydrocholesterol, cholesterol, 7-cholesta (sterol) alkanol, 26-nor-cholest-5-cholesten 3 beta-OL-25 ketone, cholest-5-en-3-one, cholest-4-en-3-one, cholest-3, 5-diene, cholest-4, 6-diene-3-one, beta-sitosterol, (3 beta, 5 alpha) cholest-7-en-3-hydroxy.
Further, the sterol component and the weight portion thereof are as follows: 24-dehydrocholesterol 1-16 parts, cholesterol 3-14 parts, cholesterol 1-16 parts, 7-cholesta (sterol) alkanol 2-10 parts, 26-cholesta-5-cholestene 3 beta-OL-25 ketone 1-15 parts, cholest-5-ene-3-ketone 2-60 parts, cholest-4-ene-3-ketone 5-150 parts, cholest-3, 5-diene 5-40 parts, cholest-4, 6-diene-3-ketone 5-40 parts, beta-sitosterol 4-60 parts, and (3 beta, 5 alpha) cholest-7-ene-3-hydroxyl 5-60 parts.
Further, the sterol component also includes pharmaceutically acceptable salts, esters, glycosides or hydrates.
Further, the soluble calcium salt is a saturated soluble calcium salt, including a saturated calcium chloride solution, a saturated calcium acetate solution, and a saturated calcium gluconate solution.
In addition, the invention also provides application of the solid dispersion of the Syngnathus sterol in preparation of drugs for preventing and treating stroke or peripheral immunosuppression caused by stroke.
Similarly, the solid dispersion of the Syngnathus sterol can also be applied to the fields of health food, food and the like.
Further, the solid dispersion of the Syngnathus sterol can be made into appropriate dosage forms such as tablets, powders, granules, capsules, syrups, suppositories, oral liquids and the like according to requirements.
Furthermore, the dose of the Syngnathus sterol is generally 1-30000 mg per day, and the dose is usually 5-10000 mg per day, preferably 30-3000 mg per adult.
The invention has the following beneficial effects:
the solid dispersion of the syngnathus sterol comprises a syngnathus sterol extract and polyvinylpyrrolidone, wherein the syngnathus sterol extract is prepared by extracting syngnathus with an alkaline methanol aqueous solution, adding a soluble calcium salt solution for precipitation, then refluxing with acetone and recrystallizing, and the obtained solid dispersion of the syngnathus sterol has good solubility, has a remarkable treatment effect on stroke, can remarkably improve peripheral immunosuppression caused by the stroke, and has the advantages of low toxicity and high safety; and the preparation method is simple, is suitable for large-scale industrial production and has wide application range.
Drawings
FIG. 1 is a standard curve diagram of cholesterol obtained by determining the purity of Syngnathus sterol according to the present invention.
FIG. 2 is a gas mass spectrum of the Syngnathus sterol extract in Experimental example 1 of the present invention.
FIG. 3 is a schematic view of the Morris water maze platform used in example 2 of the present invention.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Wherein the dried sea dragon product is prepared by mixing 1kg of acutus sea dragon, 1kg of quasi-sea dragon and 1kg of cunninghamia paniculata;
the preparation method of the alkaline methanol aqueous solution comprises the following steps: mixing methanol and water according to the volume ratio of 1:0.25, and adding 10 wt% of sodium hydroxide to obtain the catalyst.
Determination method of the purity of the Syngnathus sterol (based on the content of cholesterol):
(1) preparation of a standard curve: accurately weighing cholesterol, dissolving in n-hexane, and preparing into standard substances with different concentrations; accurately measuring 2ml of acetic anhydride in a 10ml test tube with a plug, dripping 1 drop of concentrated sulfuric acid, immediately adding 1ml of standard solution with each concentration, shaking up by vortex oscillation, standing for 10min, and measuring the absorbance of the standard solution with each concentration at the wavelength of 650 nm. The concentration of the cholesterol solution is taken as the abscissa, the OD value corresponding to the cholesterol solution is taken as the ordinate, a standard curve is drawn, and a regression equation is calculated, and the result is shown in figure 1.
(2) Sample detection: accurately weighing 65.2mg of the Syngnathus sterol extract in a 50ml volumetric flask, adding n-hexane for dissolving, and fixing the volume to obtain a sample solution to be detected; accurately absorbing 2ml of acetic anhydride, placing the acetic anhydride in a 10ml test tube with a plug, dripping 1 drop of concentrated sulfuric acid, immediately adding 1ml of diluted sample solution, shaking and uniformly mixing by vortex, standing for 10 minutes, measuring the light absorption value at 650nm, and calculating the content of total sterol according to a cholesterol standard curve.
The remaining reagents and materials used in the following examples are all commercially available unless otherwise specified.
Example 1A Syngnathus sterol solid Dispersion
The preparation method of the solid dispersion of the Syngnathus sterol comprises the following steps:
s1, micronizing 1kg of dried Syngnathus, adding 5L of alkaline methanol aqueous solution, heating and refluxing for 8h, cooling to normal temperature, and filtering to obtain filtrate;
s2, dropwise adding a saturated calcium chloride solution into the filtrate obtained in the step S2, stirring while dropwise adding until no precipitate is separated out, standing for 12 hours, and filtering to obtain a precipitate;
s3, adding 800ml of acetone into the precipitate, heating to reflux for 4 hours, filtering, concentrating the filtrate to 30% of the original volume, cooling and crystallizing, washing the crystals with 300ml of ethanol with the temperature of 4 ℃, filtering, collecting the crystals, and drying to obtain 23.5g of a Syngnathus sterol extract, wherein the purity of the Syngnathus sterol is 93% by weight;
s4, dissolving 5g of the Syngnathus sterol extract obtained in the step S3 in 1000ml of absolute ethyl alcohol, adding 100g of polyvinylpyrrolidone, heating to dissolve, uniformly mixing, and performing spray drying at 120 ℃ by using a small spray dryer to obtain 101.2g of the Syngnathus sterol solid dispersion.
Example 2A Syngnathus sterol solid Dispersion
The preparation method of the solid dispersion of the Syngnathus sterol comprises the following steps:
s1, carrying out superfine grinding on 5kg of dried sea dragon products, adding 35L of alkaline methanol aqueous solution, heating and refluxing for 8h, cooling to normal temperature, and filtering to obtain filtrate;
s2, dropwise adding a saturated calcium chloride solution into the filtrate obtained in the step S2, stirring while dropwise adding until no precipitate is separated out, standing for 12h, and filtering to obtain a precipitate;
s3, adding 2000ml of acetone into the precipitate, heating to reflux for 6h, filtering, concentrating the filtrate to 10% of the original volume, cooling and crystallizing, washing the crystals with 400ml of ethanol at 4 ℃, filtering, collecting the crystals, and drying to obtain 112.5g of the Syngnathus sterol extract, wherein the measured purity of the Syngnathus sterol is 92.6%;
s4, dissolving 10g of the Syngnathus sterol extract obtained in the step S3 in 1000ml of absolute ethanol, adding 200g of polyvinylpyrrolidone, heating to dissolve, uniformly mixing, and performing spray drying at 120 ℃ by using a small spray dryer to obtain 201.4g of the Syngnathus sterol solid dispersion.
Example 3A Syngnathus sterol solid Dispersion
The preparation method of the solid dispersion of the Syngnathus sterol comprises the following steps:
s1, carrying out superfine grinding on 7kg of dried sea dragon products, adding 65L of alkaline methanol aqueous solution, heating and refluxing for 14h, cooling to normal temperature, and filtering to obtain filtrate;
s2, dropwise adding a saturated calcium chloride solution into the filtrate obtained in the step S2, stirring while dropwise adding until no precipitate is separated out, standing for 15h, and filtering to obtain a precipitate;
s3, adding 3500ml of acetone into the precipitate, heating to reflux for 8h, filtering, concentrating the filtrate to 12% of the original volume, cooling and crystallizing, washing the crystals with 600ml of ethanol at 4 ℃, filtering, collecting the crystals, and drying to obtain 174.8g of the Syngnathus sterol extract, wherein the measured purity of the Syngnathus sterol is 93.5%;
s4, dissolving 25g of the Syngnathus sterol extract obtained in the step S3 in 6000ml of absolute ethyl alcohol, adding 900g of polyvinylpyrrolidone, heating to dissolve, uniformly mixing, and performing spray drying at 120 ℃ by using a small spray dryer to obtain 892.4g of the Syngnathus sterol solid dispersion.
Experimental example 1 detection of Syngnathus sterol extract
1. Experimental materials: example 1 Syngnathus sterol extract obtained at step S3.
2. The experimental method comprises the following steps:
accurately weighing 0.2g of Syngnathus sterol extract, adding 2ml of acetic anhydride-pyridine (volume ratio of 2:1) mixed solution, stirring and acylating at 85 deg.C for 6h to obtain sterol acetate with good volatility, adding 3ml of distilled water, extracting with n-hexane, and collecting extractive solution to be tested.
Gas chromatography conditions: TG-5SILMS capillary column, 30 m.times.0.25 mm.times.0.25 μm, carrier gas: helium gas with a flow rate of 20 ml/min; injector temperature 280 ℃; heating up, injecting sample at 80 deg.C, keeping for 3min, heating up to 100 deg.C at 10 deg.C/min in the first stage, heating up to 180 deg.C at 5 deg.C/min in the second stage, and heating up to 280 deg.C at 2 deg.C/min in the third stage. Mass spectrum conditions: ionization mode EI, electron energy 70eV, ion source temperature 250 ℃, scan speed 3.5842 s/sec.
3. The experimental results are as follows:
the results are shown in FIG. 2, and the analysis and identification results of the components are shown in Table 1 according to the cracking rule of the mass spectrum and the search result of the spectrum library.
TABLE 1 Syngnathus sterol extract contains substances
Experimental example 2 acute toxicity test of Syngnathus sterol solid Dispersion
1. Experimental materials: the solid dispersion of Syngnathus sterol prepared in example 1.
2. Subject: NIH-line mice, weighing 20 + -2 g, male and female, were provided by the medical laboratory center of Guangdong province.
3. The experimental steps are as follows:
selecting 20 healthy NIH mice with half each sex, preparing the solid dispersion of the Syngnathus sterol prepared in example 1 into a test solution of 150mg/ml, performing primary gavage on the mice with the test solution of 0.8ml/20g of body weight, continuously observing for seven days, ensuring that the mice are agile in activity, smooth in fur, free from death or abnormal reaction, and incapable of increasing the concentration and volume of the test substances and measuring the LD thereof50Therefore, the maximum tolerance test was conducted. Healthy mice were selected for 20 male and female halves, and the test solution (150mg/ml) of the solid dispersion of Syngnathus sterol was administered 10 times in 24 hours, each time 0.5ml/20g body weight, and observed for 7 days, during which time the mice were allowed to eat and drink water freely, and the mice were active, had smooth fur, and did not cause death or abnormal reaction.
4. And (4) conclusion:
the maximum tolerance of the solid dispersion of the Syngnathus sterol in mice administered by intragastric administration every day should not be less than 0.5 × 10 × 0.15 × 50 ═ 37.5g/kg, i.e. the maximum tolerance of the Syngnathus sterol extract should not be less than 5.36 g/kg. Therefore, the Syngnathus sterol extract belongs to a practically nontoxic class of substances.
Experimental example 3 Effect of Syngnathus sterol solid Dispersion on cerebral apoplexy and peripheral immunosuppression caused by cerebral apoplexy
1. Experimental materials: the solid dispersion of Syngnathus sterol prepared in example 1; positive control group: vinpocetine (purchased from Henan hong pharmaceutical Co., Ltd.).
2. Subject: female Kunming mice with the SPF grade and the weight of about 40-45 g are purchased from the experimental animal center of Zhongshan university and are bred in the central barrier facility of the experimental animal of Zhongshan university.
3. The experimental steps are as follows:
kunming mouse model for cerebral arterial thrombosis (photochemical thrombosis model): injecting chloral hydrate solution into abdominal cavity to make mouse completely anaesthetize, removing hair from two eyes to head top of neck, and sterilizing with iodophor. The skull is exposed by cutting the skin at the top of the head longitudinally along the middle of the skull, and the connective tissue membrane on the surface of the skull is removed and trimmed by a scalpel. Using bregma point as reference origin, 2.0mm at left side of sagittal suture and 2.0mm at back of coronal sutureOperating the window for operation, and grinding the exposed skull to the thickness of about 50 mu m by using a high-speed skull drill under a dissecting mirror to keep the dura mater intact. The polished bone meal was blown off with sterile compressed air and the polished surface was gently trimmed with a scalpel until clear cerebral superficial vessels were visible by dropping PBS. Injecting 0.4mL of 5% rose bengal dye solution into tail vein, immediately placing the mouse under green fluorescence emitter 5min later, irradiating the thinned skull with green exciting light at fixed point, and controlling the irradiation area to be 1mm2And the irradiation time is 15min, and the laser excites the rose bengal dye to react and damage the blood vessel at the irradiated part to form thrombus.
Before operation, a shading cover with a square leak hole with the middle side length of 1mm is made of sterile filter paper, and when laser is irradiated, other skull bones are protected from being irradiated by the laser beam. The skin of the head was sutured, and the Kunming mouse was returned to the mouse cage, taking care of the heat preservation. Healthy female Kunming mice 10 were taken as normal groups, and the normal groups were not subjected to any treatment. Taking another healthy female Kunming mouse as a false operation group, performing the operation on the Kunming mouse as above, but not injecting rose bengal dye and not irradiating laser. Stroke model animals were randomly divided into 5 groups: a model group, a positive control group (vinpocetine), a low dose administration group of the solid dispersion of the syngnathus sterol, a medium dose administration group and a high dose administration group. Beginning 2 hours after the surgical procedure, the other groups were administered intragastrically, except for the vinpocetine group by tail vein injection. 12h after the operation, the mental state of the experimental animal was observed, and the photograph was recorded.
And when the experiment is finished, respectively obtaining a pseudo-operation control group, a model group, a low-dosage group, a medium-dosage group, a high-dosage group and a positive drug group, wherein each group contains 10 drugs. At the same time, the test substances are administered by intragastric administration every day, PVP 234mg/Kg weight is administered by intragastric administration to mice in a sham operation control group and a model group, the intragastric administration dose of the hypo-dolol solid dispersion low, medium and high dose mice is 234, 468 and 936mg/Kg weight respectively, and the administration is continued for 30 days by injecting 3.9mg/Kg weight into the abdominal cavity of a positive medicament group. Starting around the administration of the experiment, training a water maze learning searching platform for the experimental animal in the first day, and then recording the total stroke, the target phenomenon stroke, the searching rate and the platform triggering times of the animal in the water maze, wherein the results are shown in the table 2. Wherein, the Morris water maze platform is provided by Zhongshan university, see FIG. 3.
The experimental animals were fasted for 12h and freely drunk the day before dissection. Recording the weight, taking blood from the eyeball, performing EDTA anticoagulation blood collection, and rapidly killing the experimental animal by a posterior cervical spine removal method. The blood was placed in a 4 ℃ freezer on a shaker, shaken and subjected to blood cell sorting analysis, the results of which are shown in Table 3.
4. The experimental results are as follows:
table 2 water maze behavioural survey (mean ± s.d.n ═ 8)
Note: compared to the normal group:△△△P<0.001; compared to the model set:*P<0.05，***P<0.001。
as can be seen from Table 2, compared with the normal group, the stroke, search rate and trigger platform frequency of the target phenomenon in the water maze of the mouse in the model group are all obviously lower than those in the normal group, thus prompting that the stroke model causes the memory function of the mouse to be reduced. Compared with the model group, the target phenomenon stroke, the search rate and the trigger platform times of the mice in the low, medium and high dose syngnathus sterol group are obviously improved, so that the syngnathus sterol is prompted to have a therapeutic effect on cerebral apoplexy, and the effect is close to that of the positive control group.
Table 3 influence of Syngnathus sterol on blood cell classification of ischemic stroke experimental animals (Mean ± s.d.n ═ 8)
Note: compared to the normal group:△△P<0.01，△△△P<0.001；compared to the model set:*P<0.05，**P<0.01，***P<0.001。
as can be seen from Table 3, compared with the normal group, the number of leukocytes, lymphocytes, neutrophils and monocytes in the blood of the mice in the model group is obviously lower than that in the normal group, and the decrease of lymphocytes is most obvious, which indicates that the stroke model causes the peripheral immunosuppression of the mice. Compared with the model group, the white cell number, the lymphocyte number, the neutrophil number and the monocyte number of mice in the low, medium and high dose groups of the Syngnathus sterol are all obviously improved, the lymphocyte increase is most obvious, and the improvement effect of the Syngnathus sterol on the peripheral immunosuppression caused by cerebral apoplexy is prompted, while the positive control group result is close to the model group and does not improve the peripheral immunosuppression effect.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (9)
1. The solid dispersion of the syngnathus sterol is characterized by comprising a syngnathus sterol extract and polyvinylpyrrolidone, wherein the syngnathus sterol extract is prepared by adding a soluble calcium salt solution for precipitation after the syngnathus is extracted by an alkaline methanol aqueous solution, and then refluxing and recrystallizing by acetone;
the preparation method of the solid dispersion of the Syngnathus sterol comprises the following steps:
s1, crushing the dried sea dragon, adding an alkaline methanol aqueous solution, heating to reflux for 4-12 h, and filtering at normal temperature to obtain a filtrate;
s2, adding soluble calcium salt dropwise into the filtrate obtained in the step S2 while stirring until no precipitate is separated out, standing, and filtering to obtain a precipitate;
s3, adding acetone into the precipitate, heating to reflux, filtering, concentrating the filtrate to 10-30% of the original volume, cooling and crystallizing, washing the crystals with ethanol at 4 ℃, filtering, collecting the crystals, and drying to obtain a Syngnathus sterol extract;
s4, dissolving the Syngnathus sterol extract obtained in the step S3 in ethanol, adding polyvinylpyrrolidone for dissolving, uniformly mixing, and performing spray drying to obtain a Syngnathus sterol solid dispersion;
the preparation method of the alkaline methanol aqueous solution comprises the following steps: methanol and water are mixed according to the volume ratio (0.125-10): 1, and adding 1-20 wt% of sodium hydroxide or potassium hydroxide to obtain the catalyst.
2. The solid dispersion of the Syngnathus sterol according to claim 1, wherein the mass ratio of the Syngnathus sterol extract to the polyvinylpyrrolidone is 1 (1-40).
3. The solid dispersion of the Syngnathus sterol according to claim 2, wherein the mass ratio of the Syngnathus sterol extract to the polyvinylpyrrolidone is 1 (2-16).
4. The Syngnathus sterol solid dispersion according to claim 1, wherein in step S1, the weight volume ratio of the dried Syngnathus to the alkaline aqueous methanol solution is (0.05-0.5): 1 g/ml.
5. The Syngnathus sterol solid dispersion according to claim 1, wherein in step S3, the weight to volume ratio of the precipitate to acetone is 1 (10-20) g/ml.
6. The Syngnathus sterol solid dispersion according to any one of claims 1 to 5, wherein said Syngnathus sterol extract comprises the following sterol components: 24-dehydrocholesterol, cholesterol, 7-cholesta (sterol) alkanol, 26-nor-cholest-5-cholesten 3 beta-OL-25 ketone, cholest-5-en-3-one, cholest-4-en-3-one, cholest-3, 5-diene, cholest-4, 6-diene-3-one, beta-sitosterol, (3 beta, 5 alpha) cholest-7-en-3-hydroxy.
7. The Syngnathus sterol solid dispersion of claim 6, wherein said sterol component and parts by weight thereof are: 1-16 parts of 24-dehydrocholesterol, 3-14 parts of cholesterol, 1-16 parts of cholesterol, 2-10 parts of 7-cholesta (sterol) alkanol, 1-15 parts of 26-cholesta-5-cholestene 3 beta-OL-25 ketone, 2-60 parts of cholest-5-ene-3-ketone, 5-150 parts of cholest-4-ene-3-ketone, 5-40 parts of cholest-3, 5-diene, 5-40 parts of cholest-4, 6-diene-3-ketone, 4-60 parts of beta-sitosterol and 5-60 parts of (3 beta, 5 alpha) cholest-7-ene-3-hydroxyl.
8. The Syngnathus sterol solid dispersion of claim 7, wherein the sterol component further comprises a pharmaceutically acceptable salt, ester, glycoside, or hydrate.
9. The use of the solid dispersion of Syngnathus sterol according to any one of claims 1-8 for the preparation of a medicament for the prevention or treatment of stroke or peripheral immunosuppression caused by stroke.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010543615.4A CN111686132B (en) | 2020-06-15 | 2020-06-15 | Syngnathus sterol solid dispersion and application thereof in treating cerebral apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010543615.4A CN111686132B (en) | 2020-06-15 | 2020-06-15 | Syngnathus sterol solid dispersion and application thereof in treating cerebral apoplexy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111686132A CN111686132A (en) | 2020-09-22 |
| CN111686132B true CN111686132B (en) | 2022-06-24 |
Family
ID=72481137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010543615.4A Active CN111686132B (en) | 2020-06-15 | 2020-06-15 | Syngnathus sterol solid dispersion and application thereof in treating cerebral apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686132B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019892A (en) * | 2007-03-06 | 2007-08-22 | 中山大学 | Solid pipefish dispersion and its prepn and application |
| CN101643495A (en) * | 2009-07-23 | 2010-02-10 | 浙江赞宇科技股份有限公司 | Method for extracting plant sterol from fatty acid or methyl ester distilled black foot thereof |
| CN103113446A (en) * | 2013-03-15 | 2013-05-22 | 北京化工大学 | Method for separating and extracting sterol from wool fat |
| CN103450307A (en) * | 2011-12-09 | 2013-12-18 | 国家海洋局第一海洋研究所 | Method for preparing high-purity monomer of cholest-4-olefin-3-ketone in syngnathus schlegeli |
| CN105963324A (en) * | 2016-05-09 | 2016-09-28 | 中山大学 | Starfish sterol solid dispersion and application thereof |
| CN107827947A (en) * | 2017-11-17 | 2018-03-23 | 浙江伊宝馨生物科技股份有限公司 | The method that high-purity sterol is extracted from the residual oil containing sterol ester |
-
2020
- 2020-06-15 CN CN202010543615.4A patent/CN111686132B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019892A (en) * | 2007-03-06 | 2007-08-22 | 中山大学 | Solid pipefish dispersion and its prepn and application |
| CN101643495A (en) * | 2009-07-23 | 2010-02-10 | 浙江赞宇科技股份有限公司 | Method for extracting plant sterol from fatty acid or methyl ester distilled black foot thereof |
| CN103450307A (en) * | 2011-12-09 | 2013-12-18 | 国家海洋局第一海洋研究所 | Method for preparing high-purity monomer of cholest-4-olefin-3-ketone in syngnathus schlegeli |
| CN103113446A (en) * | 2013-03-15 | 2013-05-22 | 北京化工大学 | Method for separating and extracting sterol from wool fat |
| CN105963324A (en) * | 2016-05-09 | 2016-09-28 | 中山大学 | Starfish sterol solid dispersion and application thereof |
| CN107827947A (en) * | 2017-11-17 | 2018-03-23 | 浙江伊宝馨生物科技股份有限公司 | The method that high-purity sterol is extracted from the residual oil containing sterol ester |
Non-Patent Citations (4)
| Title |
|---|
| 三种海龙中甾醇类成分的GC-MS分析;陶莉等;《中草药》;20090731(第7期);第1048-1049页 * |
| 我国海龙的研究进展;许东晖等;《中国海洋药物杂志》;20050430;第24卷(第2期);第51-56页 * |
| 海龙质量标准的定性研究;颜洁;《中国优秀硕士学位论文全文数据库_工程科技Ⅰ辑》;20150115(第1期);第B016-366页 * |
| 络合法从大豆油脱臭馏出物中提取植物甾醇的工艺研究;杨亦文等;《高校化学工程学报》;20060831;第20卷(第4期);第571-575页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111686132A (en) | 2020-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| CN102771791A (en) | Healthcare food and preparation method and application thereof | |
| CN104352552B (en) | A kind of food, health products or pharmaceutical composition | |
| CN101744878B (en) | Water-soluble salvia miltiorrhiza extractive, preparation and application thereof | |
| CN111686132B (en) | Syngnathus sterol solid dispersion and application thereof in treating cerebral apoplexy | |
| CN102302504A (en) | Application of high-purity baicalin or baicalein to preparation of inhaled asthma relieving medicament | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| KR20150056602A (en) | Use of 3-n-butyl isoindoline ketone in preparation of drugs for preventing and treating cerebral infarction | |
| CN110585224A (en) | Application of timosaponin BI, timosaponin IA and timosaponin AIII in preparation of medicine for treating cognitive disorder | |
| CN100581552C (en) | Compound puerarin for treating cardiovascular and cerebrovascular disease | |
| CN113456628A (en) | Application of fraxinellone in preparation of medicine for treating allergic skin diseases | |
| CN108210879A (en) | A kind of pharmaceutical composition for treating acute Cerebral bleeding and its application | |
| CN103622988B (en) | Cordycepin purposes in the medicine preparing depression and the Fast Anti antidepressant agents being prepared thereof | |
| CN111494545A (en) | A Chinese medicinal composition for treating senile dementia, and its preparation method | |
| CN101983637B (en) | Radix trichosanthis saponin and application of radix trichosanthis saponin in preparing medicine for treating ischemic cerebrovascular diseases | |
| CN109091539A (en) | A kind of traditional Chinese medicine extract composition, preparation method and its application | |
| JP2010168399A (en) | Pharmaceutical for controlling elevation of blood sugar | |
| CN106344634B (en) | A kind of mango bark extract and its preparation method and application | |
| CN116617313B (en) | A Chinese medicinal composition with antidepressant, anxiolytic and antifatigue effects, and its preparation method | |
| CN113368098B (en) | Application of icariin in preparation of medicine for preventing and treating hemophilia | |
| CN109481446B (en) | Composition for improving body functions of pregnant woman, lying-in woman and lactating mother and fetus and preparation process | |
| CN1389205A (en) | Soft bilobalide capsule and its prepn. | |
| CN115337316A (en) | Application of pharmaceutical composition in 'Junyinnaotong' capsule in treating cerebral apoplexy | |
| EP4205734A1 (en) | Application of ?-asarone in preparation of medicine for preventing or treating hemorrhagic stroke | |
| CN107820427A (en) | Herbaceous stem element or its composition are preparing the application in preventing and treating cardiovascular and cerebrovascular diseases medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |